Skip to content Skip to footer
Subscribe Now
PharmaShots Interview In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza
VIEWPOINTS

PharmaShots Interview: In Conversation with Cidara’s CEO, Dr.Jeff Stein, Where he Shares Insights on the IND acceptance by the FDA to Treat Influenza

Shots: Jeff spoke about IND acceptance by the US FDA for its lead flu drug-Fc conjugate immunotherapy for the prevention and treatment of Influenza He also discussed Cidara’s collaboration with Janssen Pharmaceuticals to develop and commercialize Cidara’s DFCs The interview also emphasizes Cidara’s Cloudbreak platform to develop immunotherapeutic antivirals and treatment options for influenza Smriti:…
June 6, 2022

Read more

Insights+ Key Biosimilars Events of May 2022
INSIGHTS+

Insights+ Key Biosimilars Events of May 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, JSR Life Sciences launches Similis Bio business…
June 2, 2022

Read more

PharmaShots Interview In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space
VIEWPOINTS

PharmaShots Interview: In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space

Shots: Thierry spoke about the IND clearance of its lead candidate in hypoparathyroidism and the company’s clinical trial plans for rare endocrine and related diseases Thierry also communicated about the closing of funding Series B equity financing round The interview gives a deeper understanding of Hypoparathyroidism and its treatment options Smriti: What did this Investigational…
June 1, 2022

Read more

PharmaShots Interview In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets
VIEWPOINTS

PharmaShots Interview: In Conversation with Pyxis’ CMO Jay M. Feingold, Where he Shares Insights on the addition of In-Licensed & Internal IO Assets

Shots: Jay talked about the in-licensing of an IND-ready immuno-oncology (IO) candidate, anti-Siglec-15 Mab to the pipeline Jay also spoke about the company’s IO targets and other under development immunotherapies In addition, the interview provided the corporate and financial updates of the Pyxis Oncology Smriti: Can you tell us something about your in-licensed Mab anti-Siglec-15,…
May 31, 2022

Read more

PharmaShots Interview MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin
VIEWPOINTS

PharmaShots Interview: MindMed’s Robert Barrow Shares Insights on Study to show Key Differences Between LSD and Psilocybin

In an interview with PharmaShots, Robert Barrow, CEO at MindMed shared his views on the Study Acute Effects of Lysergic Acid Diethylamide vs. Psilocybin in Healthy Subjects Shots: Robert spoke about the data from the peer-reviewed publication of a study comparing the acute effects of LSD and psilocybin in healthy subjects Robert also emphasized the clinical results and significance of…
May 30, 2022

Read more

PharmaShots Interview Medicago’s Brian Ward Shares Insights on COVIFENZ, a Plant-Based COVID-19 Vaccine
VIEWPOINTS

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on COVIFENZ, a Plant-Based COVID-19 Vaccine

In an interview with PharmaShots, Brian Ward, CEO at Medicago shared his views on the approval of a Plant-Based COVID-19 Vaccine in combination with GSK’s pandemic adjuvant Shots: Brian talked about the data that supported the approval of Medicago’s plant-based Covid-19 vaccine by Health Canada He focused on the safety and efficacy of the vaccine…
May 25, 2022

Read more

13th Summit on Biosimilars & Innovator Biologics
EVENTS

13th Summit on Biosimilars & Innovator Biologics

The American Conference Institute invites you to attend the 13th Summit on Biosimilars & Innovator Biologics on June 28-29, 2022, back in-person in Boston! Gain government and industry insights on the Innovator and Biosimilars Marketplace from the U.S. FTC, USPTO, AAM, BIO and leading In-House Counsel. We’ve reached an inflection point in the United States. With another major wave of loss…
May 23, 2022

Read more

Load more